Skip to content

Gross Profit at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$2.15B+15.7%
TFX
TeleflexTFX
$307.43M+20.4%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
$735.4M+8.3%
IAR
Integra LifeSciencesIART
$216.98M+11.6%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$184.8M+7.4%
PDE
Pro-Dex, Inc.PDEX
$6.13M+5.8%

Other financials

Income statement

See full
Revenue$8.7M-10.2%
Operating income$2.6M-18.6%
Net income$2.6M-14.4%
EPS (diluted)$0.82-10.9%

Balance sheet

See full
Cash & equivalents$87.4M+4.9%
Total debt$210.0K
Total equity$120.4M+2.8%
Total assets$124.4M+1.5%

Cash flow

See full
Operating cash flow$3.1M-30.4%
CapEx$130.0K-29.3%
Free cash flow$3.0M-30.4%

Valuation

See full
Market cap$219.63M+26.4%
Enterprise value$132.44M+42.5%
P/E20.3×+6.4×
P/S5.9×+1.4×

Profitability

See full
Gross margin57.9%-0.4pp
Operating margin28.8%-3.9pp
Net margin28.9%-4.1pp
FCF margin34.7%0.0pp

Returns & leverage

See full
Return on equity9.1%-1.4pp
Debt / equity
Current ratio28.6×+6.3×

Where this comes from

Calculated from Utah Medical Products’s reported figures.

The official record: Utah Medical Products’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Utah Medical Products's gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Utah Medical Products's gross profit?
Utah Medical Products (UTMD) reported gross profit of $5.28M in Q1 2026.
How has Utah Medical Products's gross profit changed year-over-year?
Utah Medical Products's gross profit decreased by 4.6% year-over-year, from $5.54M to $5.28M.
What is the long-term trend for Utah Medical Products's gross profit?
Over 4 years (2021 to 2025), Utah Medical Products's gross profit has grown at a -8.2% compound annual growth rate (CAGR), from $30.92M to $22M.
What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.